Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €55.43 EUR
Change Today +0.318 / 0.58%
Volume 1.2M
As of 2:21 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

fresenius se & co kgaa (FRE) Snapshot

Open
€55.15
Previous Close
€55.11
Day High
€55.81
Day Low
€54.51
52 Week High
03/16/15 - €56.71
52 Week Low
05/6/14 - €34.52
Market Cap
30.0B
Average Volume 10 Days
1.4M
EPS TTM
€1.97
Shares Outstanding
542.0M
EX-Date
05/21/15
P/E TM
28.1x
Dividend
€0.44
Dividend Yield
0.75%
Current Stock Chart for FRESENIUS SE & CO KGAA (FRE)

Related News

No related news articles were found.

fresenius se & co kgaa (FRE) Related Businessweek News

No Related Businessweek News Found

fresenius se & co kgaa (FRE) Details

Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment provides products for hemodialysis and peritoneal dialysis. This segment offers dialyzers, dialysis machines, and renal pharmaceuticals, as well as dialysis- related services. As of December 31, 2014, it treated approximately 285,312 patients at 3,361 dialysis clinics. The Fresenius Kabi segment provides therapy and care for chronically and critically ill patients. This segment offers intravenously administered generic drugs, such as anesthetics, anti-infectives, and analgesics, as well as drugs for the treatment of oncological and other critical diseases; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; infusion and nutrition pumps; products used in the collection and processing whole blood and blood components, as well as in transfusion medicine. The Fresenius Helios segment operated approximately 110 hospitals, including 86 acute care hospitals and 24 post acute care clinics; 47 outpatient clinics; and 15 nursing homes. The Fresenius Vamed manages projects and provides services for hospitals and other health care facilities. This segment offers project development, planning, and turnkey construction services, as well as provides maintenance, technical, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg, Germany.

216,275 Employees
Last Reported Date: 03/19/15
Founded in 1912

fresenius se & co kgaa (FRE) Top Compensated Officers

Chairman of the Management Board - Fresenius ...
Total Annual Compensation: €2.4M
Chief Financial Officer of Fresenius Manageme...
Total Annual Compensation: €1.5M
Chief Executive Officer of Fresenius Kabi
Total Annual Compensation: --
Chief Legal & Compliance Officer of Fresenius...
Total Annual Compensation: €1.1M
Member of Management Board - Fresenius Manage...
Total Annual Compensation: €2.9M
Compensation as of Fiscal Year 2014.

fresenius se & co kgaa (FRE) Key Developments

Fresenius SE & Co KGaA to Report Fiscal Year 2014 Results on Mar 19, 2015

Fresenius SE & Co KGaA announced that they will report fiscal year 2014 results on Mar 19, 2015

Fresenius SE & Co KGaA Reports Group Earnings Results for the Full Year Ended December 31, 2014; Provides Earnings Guidance for 2015 and 2017; Proposes Dividend for the Full Year Ended December 31, 2014

Fresenius SE & Co. KGaA reported group earnings results for the full year ended December 31, 2014. Group sales increased by 14% (16% in constant currency) to EUR 23,231 million against EUR 20,331 million last year. Organic sales growth was 4%. Currency translation had a negative effect of 2%. Acquisitions contributed 12%. Divestitures had a marginal effect on sales growth. Group EBIT increased by 4% (also 4% in constant currency) to EUR 3,158 million against EUR 3,045 million last year. Net income increased by 3% (4% in constant currency) to EUR 1,086 million against EUR 1,051 million last year. Earnings per share increased by 3% (3% in constant currency) to EUR 2.01 against EUR 1.96 last year, adjusted for 1:3 share split in 2014. Net income (including special items) attributable to shareholders increased by 6% (6% in constant currency) to EUR 1,067 million against EUR 1,011 million last year. Earnings per share increased by 4% (5% in constant currency) to EUR 1.97 against EUR 1.89 last year, adjusted for 1:3 share split in 2014. CapEx of 5.7% for the full year influenced by a strong fourth quarter. For 2015, Fresenius projects sales growth of 7% to 10% in constant currency. Net income is expected to increase by 9% to 12% in constant currency. For 2015, the normalization tax rate expects around 30%. For the year 2017, the company expects sales in the range of EUR 30 billion and net income of EUR 1.4 billion to EUR 1.5 billion for 2017. Based on the strong financial results, the company will propose to the Supervisory Board a dividend increase of 6% to EUR 0.44 per share against EUR 1.25 pre 1:3 share split for 2013.

Fresenius SE & Co KGaA Announces Management Changes

Fresenius SE & Co. KGaA has announced the departure of Birgit Grund, senior vice president of investor relations, effective March 31, 2015. Markus Georgi will succeed Birgit Grund as Senior vice president of Investor Relations, effective April 1, 2015. He has worked in Investor Relations for more than 15 years and will join Fresenius from Celesio AG, where he is currently Director Investor Relations. Prior to joining Celesio in 2011, Georgi was Head of Investor Relations at CompuGroup Medical AG and before that vice president Investor Relations & Head of Equity Capital Markets at Deutsche Telekom AG.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FRE:GR €55.43 EUR +0.318

FRE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FRE.
View Industry Companies
 

Industry Analysis

FRE

Industry Average

Valuation FRE Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FRESENIUS SE & CO KGAA, please visit www.fresenius.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.